You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
First multi-year cumulation covers six years: 1965-70.
"Exorbitant prices for lifesaving drugs, safety recalls affecting tens of millions of Americans, and soaring rates of addiction and overdose on prescription opioids have caused many to lose faith in pharmaceutical companies. Now, Americans are demanding national reckoning with a monolithic industry. In Pharma, award-winning journalist and New York Times best-selling author Gerald Posner uncovers the real story of the Sacklers, the family that became one of America's wealthiest from the success of OxyContin, their blockbuster narcotic painkiller at the centure of the opioid crisis. The unexpected twists and turns of the Sakler family saga are told against the startling chronicle of a powerful industry that sits at the intersection of public health and profits. Pharma reveals how and why American drug companies have put earnings ahead of patients"--
None
""Frontiers in Medicinal Chemistry" is an Ebook series devoted to the review of areas of important topical interest to medicinal chemists and others in allied disciplines. "Frontiers in Medicinal Chemistry" covers all the areas of medicinal chemistry, incl"
Humans coexist with millions of harmless microorganisms, but emerging diseases, resistance to antibiotics, and the threat of bioterrorism are forcing scientists to look for new ways to confront the microbes that do pose a danger. This report identifies innovative approaches to the development of antimicrobial drugs and vaccines based on a greater understanding of how the human immune system interacts with both good and bad microbes. The report concludes that the development of a single superdrug to fight all infectious agents is unrealistic.
A complete market research guide to the business of biotech, genetics, proteomics and related services--a tool for strategic planning, competitive intelligence, employment searches, or financial research. Complete profiles of nearly 400 leading biotech companies, in-depth chapters on trends. Includes glossary thorough indexes, statistics, research and development, emerging technology--as well a addresses, phone numbers, and executive names.
None
In the pre-antibiotic era, the infections we currently see as relatively minor were sometimes deadly. This book discusses the rise (and sometimes fall) of “wonder drugs” designed to combat infections for which, at the time, there was no cure. However, history has shown us that, when antibiotics are overused, it can ultimately lead to either widespread discontinuation of the antibiotic or a drastic decrease in efficacy, leaving healthcare providers with few or no options for treatment. This book explores the discoveries of the major antibiotic drug classes, and highlights major bacterial strains which have become resistant and now represent difficult-to-treat infections. Barriers to new antibiotic development, as well as novel strategies for treating bacterial infections, are also explored.
None